Stuart L. Goldberg, MD, On the Role of the Multidisciplinary Approach in Biomarker Testing

Article

The expert spoke about the importance of coordination to make sure every person involved with a patient’s care is in agreement as to how to treat the patient most effectively.

Stuart L. Goldberg, MD, from Hackensack University Medical Center, spoke with CancerNetwork® about the role that the multidisciplinary approach plays in biomarker testing and the importance of coordination in this setting. 

Transcription:

In order to do biomarkers, you have to coordinate and get the sample properly. Many of our patients with colon cancer, with lung cancer, they’re not seeing the oncologist first. The biopsies are being done by the pulmonologists, by the gastroenterologist, and those samples may then go to a pathologist who doesn’t think about the diagnosis, or if they get the diagnosis, they then fail to then talk to the oncologist early and send the samples off. And so, we need to coordinate between the primary care physician, the person who’s making the diagnosis at the tissue level, the pathologist who gets that sample, and the oncologist to make sure that everyone’s on the same page as to what type of genetic profiling needs to be done and how to do it in a cost effective manner. We don’t need to spend lots of money on tests that we’re not going to be doing if the patient’s not going to be getting therapy. But on the other hand, if the patient is going to be getting therapy, we want to make sure that all the right tests are being done. 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content